Research use onlyNot for human or veterinary use
Encore Bio Labs CartExplore catalog
ENCORE BIO LABSRESEARCH COLLECTION
Semax — complete Encore Bio Labs reference vialMATERIAL / 19

Reference artwork · Legacy packaging may be shown.
Listed identity and formats take precedence over the image.

Research material

Semax

Explore brain-cell responses through a seven-amino-acid peptide. Semax research in animal models examines changes in gene and protein expression. The draw is a closer look at the molecular activity behind nervous-system responses, through the lens of experimental neuroscience.

CAS
80714-61-0

Formats & reference pricing

USD
Listed formatReference price
10 mg$70 USD

Reference prices describe the listed formats. They do not confirm availability or constitute an offer for sale.

Review product documentation

For laboratory research only. Not for human or veterinary use.

About the reference identity

A seven-letter molecular reference

Semax is indexed with the seven-residue sequence Met-Glu-His-Phe-Pro-Gly-Pro, or MEHFPGP in one-letter notation. Its final three residues are proline-glycine-proline. Terminal modifications are additional chemical features, not spelling variations, so a report for a modified Semax form cannot automatically identify the unmodified reference.

Reference sequence
MEHFPGP
Sequence detail
Ends with proline–glycine–proline

Reference identity only; not a test result for current inventory.

01 / Material overview

The specifications.

Catalog identity
Semax
CAS
80714-61-0
Listed formats
10 mg
Reference price range
$70 USD
Intended setting
Qualified laboratory or institutional research
Inventory specifications
Independent inventory review pending

02 / Regulatory context

Regulatory & safety notes.

FDA’s public compounding materials can provide regulatory safety context. They do not verify a current Encore Bio Labs lot.

FDA PUBLIC RECORD · REVIEWED OCT 2026Semax

FDA compounding record · Semax

FDA lists Semax among withdrawn bulk-substance nominations and describes potential immunogenicity concerns related to aggregation and peptide-related impurities, while noting no or limited safety-related information for proposed routes of administration.

The FDA record is a safety-context statement, not an approval, efficacy claim, or current-lot verification.

FDA record type
Human drug compounding safety context
Human-use guidance
Not provided

External public record

FDA · Bulk drug substances and potential safety risks

03 / Supporting records

Documentation.

Read the Encore summary, the scope of related reports and the status of privacy-redacted supplier copies.

No authenticated certificate establishing current-inventory identity or specifications is published for Semax in this catalog.

Encore documentary summary · not a laboratory-issued COA

Report availability
2 related reports located
Formats & scope
The earlier report names N-Acetyl Semax Amidate, not plain Semax. A new report names plain Semax without a nominal sample quantity.
Report authenticity
Laboratory authentication pending
Inventory evidence review
Report-to-inventory correspondence has not been independently established. No purity, quantity or activity result is attributed to current inventory.
Outstanding review
The new plain-Semax source is held because customer branding overlaps report text; obtain a privacy-safe issuer copy. Do not infer a nominal 10 mg format from a measured result or use the modified-form report as a certificate for plain Semax.
Product-specific SDS
Not located in the reviewed PDF set; applicability and verification pending.

Document inventory reviewed October 6, 2026. Related reports were commissioned by third parties, not Encore. Original customer details and internal records are not included here.

Privacy-redacted supplier report

Report review pending

Where prepared, these are copies redacted by Encore for privacy, not laboratory-issued public versions or Encore-commissioned tests. Analytical content is not replaced with Encore results.

Copy preparation
1 source file in redacted review copies; 1 source held separately. Duplicate file formats are not additional tests.
Supplier sharing permission
Owner-confirmed for supplied reports; this does not imply a report exists for every product. Report authentication is a separate check.
Privacy review
Release review pending. Retained references and copies elsewhere can still identify the original customer; redaction does not guarantee anonymity.
Downloads
No website copy released. No download is available for this product.
Laboratory-issued public copy
Not available. Encore-prepared redactions are not an issuer reissue.

Select individual reports for release after reviewing remaining privacy exposure, sample scope and discrepancies. A prepared review packet is not a cleared public copy.

A public copy does not by itself verify current inventory. No laboratory replacement or delivery date is promised.

Explore summary & report status

04 / A closer look

Common questions.

01Which Semax formats and reference prices are listed?

10 mg: $70 USD. These are catalog quantities and reference prices, not usage instructions, stock confirmation or an offer for sale.

02Where can I find the Semax reports?

Report review pending. The Documentation section on this page lists the reviewed source status and outstanding items for this material. No public PDF is available for this product; an unreleased or missing document is not a certificate of current inventory.

03Does the image establish the contents of a lot?

No. The image is owned Encore Bio Labs reference artwork and may show legacy packaging. Use the written identity and specifications, then verify the exact lot with supporting records.

04How should research suitability be assessed?

Qualified personnel should evaluate material identity, lot-specific records, institutional requirements, and study design. Report review pending. Independent inventory review remains pending, and no product-specific SDS was located in the reviewed set. This catalog provides no personal-use or preparation guidance.

Continue the collection

Next in the catalog.

View all materials